2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 278-282
Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Biological Processes, CHIP, Hematopoiesis, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, T Cell Lymphoma, Research, AML, Clinical Research, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Pediatric
PAPER

449 Assessing the impact of donor age and single HLA mismatch in children with ALL and AML in complete remission receiving an unrelated HCT: An EBMT PDWP study

Benedetta Elena Di Majo, MD, Annalisa Ruggeri, MD2, Jacques-Emmanuel Galimard3, Arnaud Dalissier4, Giovanna Lucchini, MD5, Adriana Balduzzi, MD6, Marco Becilli, MD7, Jean-Hugues Dalle, MD8, Birgitta Versluijs9, Renata Formankova10, Cécile Renard11, Jan Styczynski12, Franca Fagioli13, Samppa Ryhänen14, Herbert Pichler15, Jochen Buechner, MD PHD16, Henrik Sengeloev17, Cecile Pochon18, Gergely Krivan Sr, MD, PhD19, Charlotte Jubert20, Jolanta Gozdzik21, Evgenios Goussetis22, Kristina Marshall23, Peter Svec Sr, MD, PhD24, Marc Ansari, MD25, Katharina Kleinschmidt26, Roland Meisel27, Krzysztof Kalwak, PhD, DSc28
1 Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
2 Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
3 EBMT Paris Study Unit, Paris, France
4 EBMT Paris Study Unit, Paris, France
5 Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
6 Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
7 Department of Hematology, Oncology and of Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
8 Pediatric Immunology and Hematology Department and CRMR aplasies médullaires, Robert Debré Hospital, Groupe Hospitalier Universitaire, Assistance Publique-Hôpitaux de Paris Nord, Université de Paris Cité, Paris, France
9 7. Princess Maxima Center/ University Hospital for Children (WKZ), Stem cell transplantation, Utrecht, Netherlands
10 8. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol and Homolka University Hospital, Prague, Czech Republic
11 Department of Pediatric Hematology and Oncology IHOP, Hospices Civils de Lyon, Lyon 1 University, Lyon, France
12 Department of Pediatric Hematology, Oncology, Immunology and Transplantology; Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland
13 Regina Margherita Children’s Hospital, Turin - Department of Pediatrics and Public Health Sciences, University of Turin, Turin, Italy
14 12. Division of Hematology, Oncology, and Stem Cell Transplantation, Children's Hospital, and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
15 St. Anna Kinderspital and Children's Cancer Research Institute (CCRI), Department of Paediatrics, Medical University of Vienna, Vienna, Austria
16 Oslo University Hospital Department of Pediatric Hematology and Oncology, Oslo, Norway
17 Rigshospitalet, Copenhagen, Denmark
18 Nancy hospital, hematological department, Nancy, France
19 17. Pediatric Hematology and Stem Cell Transplantation Department, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary
20 Paediatric Haematology Oncology Unit, Bordeaux University Hospital, Bordeaux, France
21 Department of Clinical Immunology and Transplantation, University Children's Hospital of Cracow, Jagiellonian University Medical College, Cracow, Poland
22 Stem Cell Transplant Unit, Aghia Sophia Children’s Hospital, Thivon and Papadiamantopoulou, Athens, Greece
23 Bristol Royal Hospital for Children Department of Paediatric Oncology/ BMT, Bristol, United Kingdom
24 Pediatric University Teaching Hospital BMT Unit, II Children’s Clinic, Bratislava, Slovakia
25 Cansearch Research platform for pediatric oncology and hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland, Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland
26 Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany
27 Devision of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
28 Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Wroclaw, Poland

Introduction: Younger donor age is a recognized predictor of improved hematopoietic stem cell transplantation (HCT) outcomes in adults. Biologically, grafts from older donors show reduced self-renewal and an increased risk of clonal hematopoiesis. However, the impact of donor age on outcome in children appears less pronounced and remains controversial.

Moreover, comparable outcomes after fully matched and single HLA-mismatched unrelated donor (MUD) HCT have also been reported in pediatric hematologic malignancies.

Patients and methods: We analyzed the impact of donor age and single HLA mismatch in children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in complete remission (CR1/CR2), undergoing 9/10 or 10/10 MUD HCT (BM 60.8%, PB 39.1%), with anti-thymocyte (ATG) or anti-lymphocyte globulin (ALG) use, between 2010 and 2024, reported to the EBMT. The primary outcome was the leukemia free survival (LFS). Cox-regression models assessed variables associated with outcomes. After confirming the linear association between donor age and outcomes, donor age was included in the models as a continuous variable and scaled per 10-year increase for hazard ratio (HR) interpretation. The final analysis included 1861 HCTs (10/10 n=1413; 9/10 n=448).

Results: Median recipient age at HCT was 8.7 and 9.2 years and median year of HCT was 2019 and 2018, in 10/10 and 9/10 groups, respectively. In the 9/10 group, A* was mismatched in the majority of cases (N=194, 43.3%). Median donor age was 27.4 and 28.3 years, respectively. Most ALL patients received TBI-based conditioning (784/1174, 66.8%), whereas the busulfan-based conditioning predominated in AML (560/687, 81.5%).

Interestingly, no significant impact of donor age was found on LFS (HR=0.94, 95%confidence interval[CI]: 0.83-1.05; P=0.28), overall survival (OS; HR= 0.98, 95% CI: 0.86-1.12; P= 0.78), relapse incidence (RI; HR=0.89, 95% CI: 0.77-1.03; P=0.11), non-relapse-mortality (NRM; HR=1.03, 95% CI: 0.84-1.27; P=0.75), graft-versus-host free relapse-free survival (GRFS; HR=1.03, 95% CI: 0.93-1.15; P=0.54) and chronic graft-versus-host-disease (cGVHD; HR=1.15, 95% CI: 0.97-1.36; P=0.12).

By contrast, the risk of acute GVHD (aGVHD) grade II-IV (HR=1.19, 95% CI: 1.08-1.31; P=0.001), aGVHD grade III-IV (HR=1.18, 95% CI: 1.00-1.40; P=0.049), and moderate/severe/extensive (M/S/E) cGVHD (HR=1.39, 95% CI: 1.11-1.73; P=0.004) was higher among recipients from older donors, irrespective of HLA matching.

Compared with 10/10 donors, 9/10 donors were associated with inferior LFS (HR=1.32, 95% CI: 1.08-1.62; P= 0.008), OS (HR=1.58, 95% CI: 1.26-1.98; P<0.001), NRM (HR=1.93, 95% CI: 1.36-2.73; P<0.001), GRFS (HR=1.42, 95% CI: 1.17-1.72; P<0.001), aGVHD grade II-IV (HR=1.49, 95% CI: 1.24-1.79; P<0.001) and grade III-IV (HR=1.82, 95% CI: 1.35-2.46; P<0.001).

No significant differences were found for the single mismatch group on RI (HR=1.09, 95% CI: 0.84-1.40; P=0.53), cGVHD (HR=0.98, 95% CI: 0.69-1.37; P=0.89) and M/S/E cGVHD (HR=1.31, 95% CI: 0.85-2.01; P=0.22).

Notably in ALL, HCT in CR2 was associated with inferior LFS (HR=1.41, 95% CI: 1.12-1.77; P=0.004), OS (HR= 1.31, 95% CI: 1.01-1.70; P=0.049), RI (HR=1.67, 95% CI: 1.26-2.21; P<0.001) and GRFS (HR=1.27, 95% CI: 1.03-1.58; P=0.03) compared with CR1.

Finally, the risks of cGVHD and M/S/E cGVHD were greater among PB graft recipients (HR= 1.43, 95% CI: 1.02-1.99; P=0.04; HR= 1.75, 95% CI: 1.15-2.68; P=0.009; respectively) and in female-to-male grafted recipients (HR= 1.50, 95% CI: 1.08-2.08; P=0.01; HR= 2.01, 95% CI: 1.32-3.06; P=<0.001; respectively).

Conclusion: In contrast to adults, younger donor age had limited impact on HCT outcomes in children, although older donor age increased GVHD risk. Unlike previous pediatric reports, single HLA mismatch was associated with inferior survival and higher aGVHD incidence. These findings from a large multicenter retrospective cohort suggest that donor selection priorities may warrant reconsideration. For patients lacking a 10/10 MUD, especially in pB-ALL, alternative therapeutic approaches, including novel cellular therapies, may represent valuable options.

Nonetheless, prospective studies are warranted to further define the impact of HLA mismatch and the role of donor age in donor selection for pediatric HCT. Finally, advances in GVHD prophylaxis may further improve outcomes, and our results may serve as a benchmark for future studies.

Benedetta Elena Di Majo, MD: No relevant conflicts of interest to declare.